We conducted a joint review of the portfolio management activities of the committee overseeing COVAX R&D and manufacturing investments, known as RDMIC (R&D and Manufacturing Investment Committee). Our aim was to assess learnings from investments to date and suggest ways to strengthen future global health security preparedness and prevent the inequities observed in the COVID-19 response from repeating.
CGD Policy Blogs
Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.
The World Bank’s International Development Association (IDA), the largest single source of concessional financing for development in lower-income countries, is under-utilized in the world’s fight against pandemics, and can deploy its resources and expertise to play a much more significant role in the COVID-19 response and beyond as part of its upcoming replenishment, known as IDA20.
Make Me a Match: We Want Your Ideas to Kick-Start Promising Global Health Innovations with Demand-Side Funding
Scientific and technological innovation has the potential to save lives, reduce global poverty, and help address the most pressing global challenges—but investments in R&D are mostly directed at lucrative, high-income markets versus the health problems that affect the global poor.
In this blog, we explore three key actions linked to strategic purchasing that India’s AB-PMJAY scheme can apply by leveraging its influence as a major purchaser of services and goods in the country. These same actions are readily generalizable and can replicated by other jurisdictions to save money, improve health and accelerate a country’s journey towards UHC.